PECATI Trial: Lenvatinib Plus Pembrolizumab Shows 40.2-Month Median OS in Pretreated Thymic Tumors
Patients with advanced B3-thymoma and thymic carcinoma whose disease has progressed after platinum-based chemotherapy have no standard second-line option — and a combination of lenvatinib and pembrolizumab posted a median overall survival of 40.2 months in final Phase II results published on November 13.
The final analysis of the PECATI trial, published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer, showed a median progression-free survival of 22.1 months after a median follow-up of 24.6 months. That is an improvement on the trial’s earlier analysis, which reported median progression-free survival of 14.9 months.
Dr. Jordi Remon of the University of Paris Saclay, Department of Cancer Medicine, Gustave Roussy in Villejuif, France, said the results suggest the combination could offer a possible therapeutic choice for certain patients whose cancer has advanced after platinum-based chemotherapy, though vigilant surveillance for toxicities linked to the treatment is still necessary.
The findings matter because thymic epithelial tumors are rare thoracic cancers arising in the thymus, the organ behind the breastbone, and B3-thymoma and thymic carcinoma are among their most aggressive forms. Platinum-based chemotherapy remains the standard initial treatment for advanced disease, but no established second-line standard exists when the cancer progresses, according to the study’s background.
Key Clinical Takeaways:
- The PECATI Phase II trial reported median overall survival of 40.2 months and median progression-free survival of 22.1 months with lenvatinib plus pembrolizumab in previously treated advanced thymic tumors.
- Disease control was achieved in 93% of the 43 patients, but 44.2% experienced grade 3 or higher treatment-related adverse events.
- The single-arm design and small sample size mean the combination cannot be shown superior to other treatments, and further prospective studies are needed.
Why second-line treatment is the gap
PECATI (NCT04710628) enrolled 43 patients with metastatic B3-thymoma or thymic carcinoma who had progressed after at least one platinum-based chemotherapy regimen. Patients with pre-existing autoimmune disorders were excluded, a design choice that reflects the immune-related risks of checkpoint inhibitors.

The population was heavily pretreated and advanced. Of the 43 participants, 84% had thymic carcinoma and 16% had B3-thymoma. About two out of three patients had stage IVB disease, over 50% had a minimum of three sites of metastasis, and roughly 44% had already undergone two or more prior treatment regimens for advanced disease.
Participants received oral lenvatinib at 20 mg daily and intravenous pembrolizumab at 200 mg every three weeks. Lenvatinib is a multi-targeted tyrosine kinase inhibitor with antiangiogenic properties; pembrolizumab is an immune checkpoint inhibitor. Treatment continued until disease progression, unacceptable toxicity or completion of a maximum of 35 treatment cycles.
How the survival figures matured
The trial had earlier met its primary endpoint, with a 5-month progression-free survival rate of 88.0%, according to the published analysis. The final analysis adds matured efficacy and safety data after longer follow-up.
| Outcome | Earlier analysis | Final analysis |
|---|---|---|
| Median progression-free survival | 14.9 months | 22.1 months |
| Median overall survival | — | 40.2 months |
| Overall survival at 3 years | — | 53% |
| Objective response rate | — | 25.6% (one complete response) |
| Disease control rate | — | 93% |
The median duration of response was not reached, suggesting that responses were sustained in some patients.
The toxicity bill
Efficacy came with a substantial safety burden. Treatment-related adverse events of grade 3 or above affected 44.2% of patients, and 27.9% stopped taking at least one study drug as a result of toxicity linked to the treatment.
Immune-related adverse events affected 39.5% of patients, with severe instances of colitis, pneumonitis, myocarditis, encephalitis and liver toxicity among them. The rate of grade 3 immune-related adverse events was 11.6%. Two patients — 4.7% of the cohort — died during the study of events investigators considered unrelated to treatment.
Investigators characterized the safety profile as manageable but advised close monitoring. For patients and oncologists weighing this combination, that means proactive management of immune-related and antiangiogenic toxicities — the kind of surveillance that typically requires a thoracic oncology team experienced with checkpoint inhibitors and kinase inhibitors, alongside specialists who can manage colitis, pneumonitis or liver toxicity if they arise.
What the trial cannot show
Dr. Remon cautioned that the study’s relatively small sample size and single-arm design mean the results cannot establish that the combination is superior to other treatments. The study also cannot determine the individual contribution of each drug to the observed outcomes.
According to Dr. Remon, further prospective studies will be needed to determine the optimal treatment sequence, identify the patients most likely to benefit, and establish whether these combinations can improve outcomes while maintaining acceptable safety.
One such study is already underway. A Phase II investigator-initiated trial known as Artemis (NCT05832827), sponsored by the National Cancer Center in Japan, is investigating carboplatin and paclitaxel combined with lenvatinib and pembrolizumab as first-line therapy for advanced or recurrent thymic carcinomas. That trial addresses a different question — whether the drugs work earlier in treatment rather than after platinum failure.
Where this leaves patients today
For now, the combination is not an established standard of care in the second-line setting. The mature PECATI results provide additional evidence supporting a potential role for lenvatinib plus pembrolizumab in selected patients with previously treated advanced thymic tumors — a population for whom options after platinum failure have been limited.
Patients with progressive B3-thymoma or thymic carcinoma who want to discuss whether a trial or an off-protocol combination is appropriate should raise it with a thoracic oncologist familiar with rare thymic malignancies, since trial eligibility — including the autoimmune-disorder exclusion applied in PECATI — shapes who can receive this regimen.
With 53% of PECATI participants alive at three years in a cohort where more than half had three or more metastatic sites, the final analysis gives the field its clearest long-term signal yet for this combination — and a benchmark that the Artemis trial and any future randomized studies will be measured against.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.